Skip to main content
Clinical Trials/NCT01459588
NCT01459588
Completed
Phase 3

Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease

Allergan0 sites315 target enrollmentOctober 1, 2011

Overview

Phase
Phase 3
Intervention
Carboxymethylcellulose Based Eye Drop Formulation A
Conditions
Dry Eye Syndromes
Sponsor
Allergan
Enrollment
315
Primary Endpoint
Change From Baseline in Ocular Surface Disease Index© Questionnaire Score
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This study will evaluate the safety, efficacy, and acceptability of an eye drop formulation in subjects with dry eye disease.

Registry
clinicaltrials.gov
Start Date
October 1, 2011
End Date
February 15, 2012
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Allergan
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Current use of eye drops for dry eye at least twice daily, on average for at least 3 months

Exclusion Criteria

  • Cataract, laser-assisted in situ keratomileusis (LASIK), or photorefractive keratectomy (PRK) surgery in the last 12 months
  • Need to wear contact lenses during the study, or has worn contact lenses in the last 6 months
  • Active ocular allergy

Arms & Interventions

Carboxymethylcellulose Based Eye Drop Formulation A

Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.

Intervention: Carboxymethylcellulose Based Eye Drop Formulation A

Carboxymethylcellulose Based Eye Drop Formulation B

Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.

Intervention: Carboxymethylcellulose Based Eye Drop Formulation B

Carboxymethylcellulose Preservative-Free Lubricant Eye Drops

Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.

Intervention: Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops

Carboxymethylcellulose Based Lubricant Eye Drops

Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.

Intervention: Carboxymethylcellulose Based Lubricant Eye Drops

Outcomes

Primary Outcomes

Change From Baseline in Ocular Surface Disease Index© Questionnaire Score

Time Frame: Baseline, Day 30

The Ocular Surface Disease Index© Questionnaire is a 12-item survey assessing the overall severity of dry eye disease per patient. Each question is rated on a 5-point scale ranging from 0=none of the time to 4=all of the time for a total possible score of 0=No disease to 100=Maximum severity of disease. A negative change from baseline indicates improvement.

Secondary Outcomes

  • Change From Baseline in Tear Break-up Time(Baseline, Day 30)
  • Change From Baseline in Corneal Staining(Baseline, Day 30)
  • Change From Baseline in Conjunctival Staining(Baseline, Day 30)
  • Change From Baseline in Schirmer Test Results(Baseline, Day 30)

Similar Trials